1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea,
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate,
Cabaser,
Cabaseril,
cabergoline,
cabergoline diphosphate,
Dostinex,
FCE 21336,
FCE-21336,
Galastop,
cabergoline,
Dostinex,
81409-90-7,
Cabaser,
Cabergolina,
Cabergolinum,
Cabaseril,
Cabergolinum [Latin],
Cabergolina [Spanish],
FCE-21336,
UNII-LL60K9J05T,
C26H37N5O2,
FCE 21336,
BRN 6020775,
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea,
CHEBI:3286,
LL60K9J05T,
Galastop,
MFCD00867887,
DSSTox_CID_2719,
DSSTox_RID_76698,
DSSTox_GSID_22719,
Sogilen,
Dostinex (TN),
Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-,
Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-,
Cabaser (TN),
CAS-81409-90-7,
Cabergoline [USAN:BAN:INN],
SR-05000001493,
Caberlin,
Cabergoline (JAN/USAN/INN),
NCGC00167821-01,
Cabergoline [USAN:USP:INN:BAN],
CG-101,
GTPL37,
AC1L1HO0,
AC1Q5OQ0,
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate,
SCHEMBL42292,
BIDD:GT0775,
CHEMBL1201087,
DTXSID6022719,
Cabergoline, >=98% (HPLC),
CTK8F8406,
KORNTPPJEAJQIU-KJXAQDMKSA-N,
HMS2090A09,
ZINC3800008,
Tox21_112589,
BDBM50426497,
1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea,
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea,
AKOS015961587,
Tox21_112589_1,
DB00248,
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide,
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea,
NCGC00344544-01,
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide,
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide,
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide,
AC-26126,
AN-36255,
BC207368,
K450,
LS-64370,
SC-19831,
FT-0081285,
FT-0650562,
C08187,
D00987,
AB01275484-01,
409C907,
SR-05000001493-1,
SR-05000001493-2,
BRD-K86882815-001-01-6,
Cabergoline, European Pharmacopoeia (EP) Reference Standard,
Cabergoline, United States Pharmacopeia (USP) Reference Standard,
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea,
6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide,
N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide,
(6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide,
(9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide,
1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carbonyl]urea,
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0;{2,7}.0;{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea,
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea,
Neutral Violet Bl,
Cabergoline diphosphate,
D04EGX,
Cabergoline [USAN:INN:BAN],
CID54746,
C26-H37-N5-O2,
CS-O-06311,
B3541,
A13844,
C047047,
D000077465,
(8-beta)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)ergoline-8-carboxamide,
Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-,